Deep brain stimulation (DBS) is an effective treatment for several movement disorders, including Parkinson's disease (PD), Essential Tremor (ET), and dystonia. While this treatment has been available for decades, mainly targeting subthalamic nucleus (STN), thalamic ventral intermediate nucleus (VIM), and globus pallidus internus (GPi) stimulation, studies on early- or long-term patient outcomes have been limited.
Most of the longitudinal DBS studies have included a mean follow-up time between 2 and 6 years and, in general, there are few data available on the early- or long-term DBS outcomes of this procedure. Because of several gaps in understanding DBS mechanisms, measuring the effect of DBS and its efficacy is of great interest. Biomarkers, such as multiple CNS and peripheral proteins, allow for the surveillance of treatment through assessment of physiological changes and even subtle alterations in treatment implementation and use. The use of electrophysiological, neuroimaging, and multiple CNS and peripheral proteins could be useful as biomarkers for DBS changes.
Topics editors welcome Original research, Brief research report, Clinical trial, Clinical study protocols, Clinical case report, Study protocols, and Reviews, about, but not limited to:
• Investigation on early- and long-term clinical effects of Deep brain stimulation (DBS) treatment in Parkinson's disease (PD), Essential Tremor (ET), and dystonia.
• Investigations on the effects of DBS treatment on clinical improvement, cognitive function, and neuropsychiatric profile, as well as activities of daily living outcomes over early- and long-term follow-up.
• Studies aiming at a better assessment of the efficacy of implemented DBS and its potential mechanism of action by a panel of established and standardized biomarkers, which spans a range of metabolic and physiologic processes to include electrophysiological brain mapping, neuroimaging, and metabolic markers.
Deep brain stimulation (DBS) is an effective treatment for several movement disorders, including Parkinson's disease (PD), Essential Tremor (ET), and dystonia. While this treatment has been available for decades, mainly targeting subthalamic nucleus (STN), thalamic ventral intermediate nucleus (VIM), and globus pallidus internus (GPi) stimulation, studies on early- or long-term patient outcomes have been limited.
Most of the longitudinal DBS studies have included a mean follow-up time between 2 and 6 years and, in general, there are few data available on the early- or long-term DBS outcomes of this procedure. Because of several gaps in understanding DBS mechanisms, measuring the effect of DBS and its efficacy is of great interest. Biomarkers, such as multiple CNS and peripheral proteins, allow for the surveillance of treatment through assessment of physiological changes and even subtle alterations in treatment implementation and use. The use of electrophysiological, neuroimaging, and multiple CNS and peripheral proteins could be useful as biomarkers for DBS changes.
Topics editors welcome Original research, Brief research report, Clinical trial, Clinical study protocols, Clinical case report, Study protocols, and Reviews, about, but not limited to:
• Investigation on early- and long-term clinical effects of Deep brain stimulation (DBS) treatment in Parkinson's disease (PD), Essential Tremor (ET), and dystonia.
• Investigations on the effects of DBS treatment on clinical improvement, cognitive function, and neuropsychiatric profile, as well as activities of daily living outcomes over early- and long-term follow-up.
• Studies aiming at a better assessment of the efficacy of implemented DBS and its potential mechanism of action by a panel of established and standardized biomarkers, which spans a range of metabolic and physiologic processes to include electrophysiological brain mapping, neuroimaging, and metabolic markers.
